Cristal Therapeutics starts clinical Phase I trial with nanomedicine CriPec docetaxel in patients with solid tumours
The CriPec platform allows for the rational design of custom-made nanomedicines for controlled release of the drug at the desired site of action resulting in an improved efficacy and tolerability.
Cristal Therapeutics has announced the recent start of a clinical Phase I trial with its lead candidate CriPec docetaxel in patients with solid tumours. For this trial, patients are being recruited in two clinical centres in The Netherlands and in Belgium. The first trial data will be available in the course of Q2 2016.
Cristal Therapeutics has developed a pioneering approach to transform existing drugs against cancer, like docetaxel, and other diseases, into tailor-made nanoparticles via its proprietary polymeric technology, registered as CriPec. The CriPec platform allows for the rational design of custom-made nanomedicines for controlled release of the drug at the desired site of action resulting in an improved efficacy and tolerability.
CriPec docetaxel is Cristal Therapeutics’ lead candidate in development and represents a novel treatment approach of solid tumours. CriPec docetaxel successfully passed various pre-clinical studies, demonstrating a significantly improved safety and tolerability profile. Current docetaxel-containing products often have limited efficacy, and prolongation of survival comes with a high incidence of adverse events. This imposes major limitations on the current therapy. CriPec nanoparticles accumulate in tumour tissue, resulting in a significantly higher CriPec docetaxel exposure of the tumour, thereby overcoming drawbacks of conventional docetaxel therapies
.Joost Holthuis, CEO of Cristal Therapeutics says: “We are very excited about the start of the clinical Phase I trial. The outcome of our pre-clinical program has been very encouraging and highlights the clinical potential of CriPec docetaxel. We are looking forward to advance this compound quickly into the Phase I- Part II trial that is expected to start next year. If successful, this will enable chemotherapy to be applied more effectively, with fewer adverse events, which is in the interest of patients with solid tumours worldwide.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance